Understand the source comparison
Comparison Table: Best Peptides for Depression by Mechanism and Clinical Evidence
The following table compares the best peptides for depression based on primary mechanism of action, administration route, evidence quality, and research focus areas. Each peptide targets distinct neurobiological pathways, making direct efficacy comparisons dif
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the best peptides for depression based on primary mechanism of action, administration route, evidence quality, and research focus areas. Each peptide targets distinct neurobiological pathways, making direct efficacy comparisons difficult without head-to-head trials. This table provides a framework for understanding their relative strengths and research maturity.
- Semax (ACTH 4-10)
- Melanocortin receptor agonist → BDNF upregulation via CREB phosphorylation
- Intranasal (0.1–1.0 mg/day)
- Open-label human trials (Russia), extensive pre-clinical data
- Treatment-resistant MDD, cognitive enhancement, stroke recovery
- Most studied for rapid-onset mood improvement; 14-day trial showed 43% HDRS reduction. Strong BDNF evidence.
- Selank (Tuftsin analogue)
- Enkephalinase inhibition + IL-10 upregulation; GABAergic modulation
- Intranasal (0.15–0.3 mg/day)
- Randomized controlled trials for anxiety; secondary depression outcomes
- Anxiety-depression comorbidity, neuroinflammatory depression
- Best for inflammation-driven or anxiety-comorbid MDD; 38% HARS reduction in RCTs. Anti-inflammatory pathway unique.
- Cerebrolysin
- Neurotrophic factor mixture (BDNF/NGF/CNTF mimetic); Trk receptor activation
- Intravenous (10–30 mL over 10–21 days)
- Meta-analysis (n=842); multiple RCTs for post-stroke depression
- Vascular depression, post-stroke MDD, elderly populations
- Strongest evidence for vascular/post-stroke depression; 35–50% symptom reduction. Requires clinical administration.
- P21 (CNTF derivative)
- CNTF receptor agonist → JAK/STAT pathway; synaptogenesis
- Subcutaneous (research models only)
- Pre-clinical only; no published human trials
- Synaptic density restoration, treatment-resistant MDD (theoretical)
- Promising pre-clinical synaptic data but zero human trials. Mechanistic overlap with Cerebrolysin suggests potential.
- Dihexa
- HGF mimetic → c-Met receptor activation; potent synaptogenesis (6–7× BDNF potency)
- Oral or subcutaneous (research models)
- Pre-clinical rodent models; no human depression trials
- Cognitive decline, anhedonia, synaptic loss in chronic stress
- Highest synaptogenic potency in vitro; oral bioavailability. No human mood data. Purely pre-clinical at this stage.